Prothena Corporation PLC
NASDAQ:PRTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Prothena Corporation PLC
NASDAQ:PRTA
|
IE |
|
Target Healthcare REIT PLC
LSE:THRL
|
UK |
|
Dajin Heavy Industry Co Ltd
SZSE:002487
|
CN |
|
A
|
Arcs Co Ltd
TSE:9948
|
JP |
|
C
|
Cembre SpA
MIL:CMB
|
IT |
|
Picton Property Income Ltd
LSE:PCTN
|
UK |
|
A
|
Antong Holdings Co Ltd
SSE:600179
|
CN |
|
Doshisha Co Ltd
TSE:7483
|
JP |
|
Central Automotive Products Ltd
TSE:8117
|
JP |
|
M
|
Maharashtra Scooters Ltd
NSE:MAHSCOOTER
|
IN |
Prothena Corporation PLC
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
Pipeline Advancements: Two partnered programs, prasinezumab (with Roche) for Parkinson's disease and coramitug (with Novo Nordisk) for ATTR cardiomyopathy, advanced to Phase III trials in 2025.
Upcoming Milestones: Prothena could earn up to $105 million in clinical milestone payments in 2026, contingent on enrollment and advancement decisions by partners.
Financial Performance: 2025 financial results were in line or better than guidance, with net cash used at $163.7 million and a year-end cash position of $308.4 million.
2026 Guidance: Net cash used in operating and investing activities expected between $50 million and $55 million, and year-end cash projected at $255 million.
CYTOPE Technology: Prothena introduced its CYTOPE platform for targeting intracellular disease pathways, highlighting promising ALS (TDP-43) preclinical data and ongoing collaboration interest.
Shareholder Returns: The company received approval and plans to implement a share redemption program in 2026.
